<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15148">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00201825</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-0356</org_study_id>
    <secondary_id>NCI-2011-03593</secondary_id>
    <nct_id>NCT00201825</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients</brief_title>
  <official_title>A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tony Bekaii-Saab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the objective response rate in chemotherapy naive non-small cell
      lung cancer patients with advanced disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Docetaxel has some efficacy against non-small cell lung cancer (NSCLC). This drug
      is Food and Drug Administration approved in combination with cisplatin (Platinol) for the
      treatment of unresectable, locally advanced or metastatic NSCLC in patients who have not
      previously had chemotherapy for this condition. Docetaxel is also approved for second line
      treatment of metastatic NSCLC. Research indicates that capecitabine, in combination with
      docetaxel, has efficacy against NSCLC. Capecitabine appears to have anti-cancer activity
      through several enzymes. This drug is metabolized in the body to another agent called 5-FU.
      During this conversion process, 5-FU requires thymidine phosphorylase (TP), a cellular
      characteristic associated with tumor growth. There are higher levels of TP expression in
      tumors as compared to normal tissue. The drug administration schedule in this study is
      designed to optimize efficacy against the TP target through both docetaxel and capecitabine.
      This study will measure biological changes to TP and other enzymes to help researchers gain
      more information about how capecitabine and docetaxel works against NSCLC.

      Purpose: This study will evaluate the efficacy of docetaxel and capecitabine in patients
      with previously untreated advanced NSCLC. Tests related to tumor biology will be conducted
      before and during study treatments and correlated with patient responses to therapies.

      Treatment: Patients in this study will receive docetaxel and capecitabine. Docetaxel will be
      administered through intravenous infusions. Capecitabine will be provided through oral
      pills. A four-week period constitutes one cycle. Docetaxel will be given weekly for three
      weeks followed by one week of rest. Capecitabine will be taken twice daily on days 5 through
      14 of the treatment cycle. Several tests and exams will be given throughout the study to
      closely monitor patients. Treatments will be discontinued due to disease growth or
      unacceptable side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Determine Objective Response Rate</measure>
    <time_frame>Every 35 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression</measure>
    <time_frame>Every 35 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One Year Survival</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Cycle 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Docetaxel and Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.</description>
    <arm_group_label>Docetaxel and Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>36 mg/m2 IV weekly for 3 weeks every 4 weeks.</description>
    <arm_group_label>Docetaxel and Capecitabine</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have advanced NSCLC

          -  No prior chemotherapy

          -  Eastern Cooperative Oncology Group(ECOG)Performance Status:0 or 1

          -  Must have measurable disease (RECIST criteria)

          -  life expectancy of at least 12 weeks

          -  adequate organ function including

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Psychiatric disorders that would interfere w/consent or follow-up

          -  Patients with uncontrolled diabetes mellitus, defined as random blood sugar &gt;
             250mg/dL.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tony Bekaii-Saab</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <results_reference>
    <citation>Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MA. A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2013 Jan;79(1):27-32. doi: 10.1016/j.lungcan.2012.09.013. Epub 2012 Oct 16.</citation>
    <PMID>23079156</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 1, 2014</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <firstreceived_results_date>September 25, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Tony Bekaii-Saab</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Previously Untreated</keyword>
  <keyword>Advanced</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled and received treatment between December 2004 and November 2007</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Docetaxel and Capecitabine</title>
          <description>Capecitabine: 1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
Docetaxel: 36 mg/m2 IV weekly for 3 weeks every 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible patients had histologically confirmed advanced NSCLC and had not received prior chemotherapy.</population>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel and Capecitabine</title>
          <description>Capecitabine: 1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
Docetaxel: 36 mg/m2 IV weekly for 3 weeks every 4 weeks.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61" lower_limit="39" upper_limit="76"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>patients</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>patients</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>patients</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Histology</title>
          <units>patients</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Adenocarcinoma</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Squamous cell carcinoma</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Large cell Carcinoma</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>NSCLC not specified</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>ECOG (Eastern Cooperative Oncology Group)</title>
          <units>patients</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Performance status 0 (Fully active)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Performance status 1 (Restricted activity)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine Objective Response Rate</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>Every 35 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>One patient was not evaluable for response because the patient was removed from study afer an adverse event.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Capecitabine</title>
            <description>Capecitabine: 1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
Docetaxel: 36 mg/m2 IV weekly for 3 weeks every 4 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Determine Objective Response Rate</title>
            <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
            <units>patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Complete response (CR)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Partial response (PR)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stable Disease</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Disease Progression</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Overall response (CR + PR)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Progression</title>
        <time_frame>Every 35 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Capecitabine</title>
            <description>Capecitabine: 1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
Docetaxel: 36 mg/m2 IV weekly for 3 weeks every 4 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to Tumor Progression</title>
            <units>months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.3" lower_limit="1.5" upper_limit="4.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>One Year Survival</title>
        <time_frame>one year</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Capecitabine</title>
            <description>Capecitabine: 1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
Docetaxel: 36 mg/m2 IV weekly for 3 weeks every 4 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>One Year Survival</title>
            <units>months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10.5" lower_limit="3.2" upper_limit="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics</title>
        <time_frame>Cycle 2</time_frame>
        <safety_issue>No</safety_issue>
        <population>No Pharmacokinetics were conducted for this trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Capecitabine</title>
            <description>Capecitabine: 1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
Docetaxel: 36 mg/m2 IV weekly for 3 weeks every 4 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pharmacokinetics</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed using the NCI Common Toxicity Criteria version 3.0 from week 1 of the study until end of study.</time_frame>
      <desc>Adverse events will use the descriptions and grading scales found in the revised NCI Common Toxicity Criteria (CTC). This study will utilize the CTC version 3.0 for toxicity and Adverse Drug Experience reporting.</desc>
      <group_list>
        <group group_id="E1">
          <title>Docetaxel and Capecitabine</title>
          <description>Capecitabine: 1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
Docetaxel: 36 mg/m2 IV weekly for 3 weeks every 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tanios Bekaii-Saab, MD</name_or_title>
      <organization>The Ohio State University Comprehensive Cancer Center</organization>
      <phone>614-293-6529</phone>
      <email>Tanios.Saab@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
